At the end of the three weeks the mean reduction from baseline in the primary efficacy variable, trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose), 13.2 mmHg (high dose).
11, 7 mmHg (madal annus), 9, 3 mmHg (keskmine annus), 13, 2 mmHg (kõrge annus).